JNJ Related Corporate News
-
J&J's (JNJ) Janssen Receives Priority Review from FDA for Simeprevir
-
J&J's (JNJ) Janssen Sells 82M Elan (ELN) ADS
-
Janssen-Cilag (JNJ) Submits MA to EMA for Canagliflozin, Metformin in Type 2 Diabetes
-
Johnson & Johnson (JNJ) Sees 4c/Share Hit on EPS From Bolivar Devaluation
-
Idenix (IDIX) Enters Collaboration with Janssen Pharma for DAA HCV Evaluatlion
-
J&J (JNJ) Updates on Growth Strategies, Looking at Options for OCD Business
-
Janssen (JNJ) Submits NDA for Canagliflozin to FDA
-
Janssen Approved for Expanded Indication of ZYTIGA (JNJ)
-
J&J's (JNJ) Janssen Receives FDA Panel Backing for MDR-TB Drug Bedaquiline
-
J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing
-
J&J's (JNJ) Janssen Receives Position EMA CHMP Opinion for ZYTIGA as mCRPC Treatment
-
J&J's (JNJ) Janssen Reports Significant Phase 3 Data from Golimumab on Radiographic Progression in RA Patients
-
J&J's (JNJ) Janssen Reports Significant Findings from PSUMMIT II on Psoriatic Arthritis
-
Vertex (VRTX) Pops Higher, Enters Two New HCV Treatment Collaborations
-
J&J (JNJ) to Present New TMC435 Data on HCV at AASLD in Nov.
-
J&J's (JNJ) Janssen-Cilag Gets EC Approval for DACOGEN in AML
-
J&J's (JNJ) Janssen Unit Submits BLA for Anti-TNF)-alpha SIMPONI
-
Johnson & Johnson (JNJ) Takes New Approach to Innovation
-
Johnson & Johnson's (JNJ) Janssen Granted Priority Review for TMC207 NDA
-
J&J's (JNJ) Janssen Settles RISPERDAL Suit w/ 36 States and D.C.; Will Pay $181M
-
Janssen Says ZYTIGA sNDA Received Priority Review Status from FDA (JNJ)
-
Elan (ELN) Updates Investors on Bapineuzumab Discontinuation
-
Johnson & Johnson (JNJ) Says Bapineuzumab IV in Alzheimer's Stopped
-
J&J (JNJ) Issues Statement of Proposed Settlement in Derivative Litigation
-
J&J (JNJ) Close to Mult-Billion Dollar Settlement Over Illegal Anitpsychotic Drug Marketing
-
J&J's (JNJ) Janssen-Cilag Submits Additional Marketing Application for ZYTIGA
-
Johnson & Johnson (JNJ) Clears Final Regulatory Hurdle in Synthes Acquisition; Sets Closing Date
-
Janssen, Johnson & Johnson (JNJ) to Present Data from Five Pivotal Canagliflozin Phase 3s
-
J&J (JNJ) Receives FDA Warning Letter Related to K-Y Vaginal Moisturizer -WSJ
-
J&J (JNJ) Says FDA Issued CRL for Janssen's 800mg PREZISTA
-
Committee Recommends J&J's (JNJ) ZYTIGA Study Be Unblinded Amid Better Survival Data
-
Supreme Court Rejects J&J's (JNJ) Request to Reinstate Ruling Against Abbott (ABT) -Bloomberg
-
Merck (MRK) Shows Strong Earnings Following M&A Adjustments; Outlook Flat
-
Boston Scientific (BSX) Gets Favorable Ruling in Patent Case with J&J (JNJ)
-
Employee Advocacy Group Demands Separation of Chair, CEO Roles at 9 Large Publicly-Traded Companies
-
Janssen Biotech (JNJ) Announces Agreement with Pharmacyclics (PCYC) to Devlop Anti-Cancer Compound
-
Pharmacyclics (PCYC) Enters PCI-32765 Collaboration w/ J&J (JNJ) Unit; to Get $150M Upfront
-
ImmunoGen (IMGN) to Discontinue IMGN388 Development, Will Refocus Resources
-
Affymax (AFFY) Settles with J&Js (JNJ) Janssen Biotech; Will Pay $13M in Fees, Milestones
-
EC Opens Investigation on J&J (JNJ) Over Fentanyl Patches (NVS)
-
Shares of Anadys (ANDS) Trade Above $1; Analyst Believes Co. Could Get a Bid Following Setrobuvir Data
-
Boston Scientific's (BSX) NIR Stent Found Not to Infringe on J&J's (JNJ) Fischell Patent
-
Johnson & Johnson (JNJ), Bayer Receive Favorable FDA Panel Vote for Xarelto
-
BioClinica (BIOC) Announces Clinical Trial Efficiency Improvements with Johnson and Johnson Vision Care
-
Johnson & Johnson (JNJ) To Cut 900-1000 Jobs, Expects $500-$600 Million Special Charge Following Cordis Restructuring
-
J&J (JNJ) Announces Special Charge of $500-$600M in Q2 for Restructuring of Cordis; to Cut 900-1,000 Jobs
-
Court of Appeals Affirms Decision in Favor of Boston Scientific (BSX)
-
J&J (JNJ) Being Probed by Prosecutors Over Risperdal -WSJ
-
Johnson & Johnson (JNJ) Issues Q1 'Beat-and-Raise' Led By Pharma Business
-
Johnson & Johnson (JNJ) to Pay $70M to SEC in Corrupt Practices Settlement
Back to JNJ Stock Lookup
